Disease Information

General Information of the Disease (ID: DIS00370)

• Name: Transitional cell carcinoma
• ICD: ICD-11: 2C9Z

Type(s) of Resistant Mechanism of This Disease

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Drug

Approved Drug(s) 2 drug(s) in total

Erdafitinib

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Fibroblast growth factor receptor 3 (FGFR3) [1]

• Sensitive Disease: Transitional cell carcinoma [ICD-11: 2C9Z.0]
• Molecule Alteration: Missense mutation; p.S249C (c.746C>G)
• Sensitive Drug: Erdafitinib
• Experimental Note: Identified from the Human Clinical Data

Key Molecule: Fibroblast growth factor receptor 3 (FGFR3) [1]

• Sensitive Disease: Transitional cell carcinoma [ICD-11: 2C9Z.0]
• Molecule Alteration: Missense mutation; p.G370C (c.1108G>T)
• Sensitive Drug: Erdafitinib
• Experimental Note: Identified from the Human Clinical Data

Key Molecule: Fibroblast growth factor receptor 3 (FGFR3) [1]

• Sensitive Disease: Transitional cell carcinoma [ICD-11: 2C9Z.0]
• Molecule Alteration: Missense mutation; p.Y373C (c.1118A>G)
• Sensitive Drug: Erdafitinib
• Experimental Note: Identified from the Human Clinical Data

Key Molecule: Fibroblast growth factor receptor 3 (FGFR3) [1]

• Sensitive Disease: Transitional cell carcinoma [ICD-11: 2C9Z.0]
• Molecule Alteration: Missense mutation; p.R248C (c.742C>T)
• Sensitive Drug: Erdafitinib
• Experimental Note: Identified from the Human Clinical Data

Infigratinib

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Fibroblast growth factor receptor 3 (FGFR3) [2]

• Resistant Disease: Transitional cell carcinoma [ICD-11: 2C9Z.0]
• Molecule Alteration: Missense mutation; p.V555M (c.1663G>A)
• Resistant Drug: Infigratinib
• Experimental Note: Identified from the Human Clinical Data

References

• Ref 1: Erdafitinib in Locally Advanced or Metastatic Urothelial CarcinomaN Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323.
• Ref 2: Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 AlterationsCancer Discov. 2018 Jul;8(7):812-821. doi: 10.1158/2159-8290.CD-18-0229. Epub 2018 May 30.